港股公告掘金 | 國泰航空上半年股東應佔溢利36.51億港元百濟神州上半年業績扭虧為盈至9559萬美元

智通財經

08/06

【重大事項】

國泰航空(00293)購買十四架波音777-9型飛機

恆瑞醫藥(01276)：注射用瑞康曲妥珠單抗聯合阿得貝利單抗注射液和化療用於胃癌或胃食管結合部腺癌適應症獲得美國 FDA孤兒藥資格認定

中國生物製藥(01177) 自主研發的羅伐昔替尼片「TQ05105 (JAK/ROCK抑制劑)」被納入突破性治療藥物程序

復宏漢霖(02696)：HLX79注射液聯合漢利康® 治療活動期腎小球腎炎的2期臨牀研究於中國境內完成首例患者給藥

瑛泰醫療(01501)擬出資不超過1.1億元參設懷格廣泰基金

晉景新能(01783)建議股份拆細

【財報數據】

國泰航空(00293)發佈中期業績股東應占溢利36.51億港元同比增長1.1% 中期息每股20港仙

統一企業中國(00220)發佈中期業績，股東應占溢利12.87億元，同比增加33.24%

百濟神州(06160)發佈第二季度業績淨利潤9432萬美元同比扭虧為盈

新鴻基公司(00086)發盈喜預計中期股東應占溢利同比增加至不低於8億港元

維信金科(02003)發盈喜，預期中期綜合淨利潤不少於2億元同比大幅增長

赤子城科技(09911)發盈喜預計中期股東應占利潤同比增長約108.9%至126.7%

華顯光電(00334)發盈喜預期上半年母公司擁有人應占溢利同比增加不少於600%

信利國際(00732)7月綜合營業淨額約14.68億港元，同比減少約3.3%

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557058673"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557058673\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557058673?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-06 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557058673","market":"fut","top_or_hot":-1,"title":"港股公告掘金 | 國泰航空上半年股東應佔溢利36.51億港元 百濟神州上半年業績扭虧為盈至9559萬美元","media":"智通財經","content":"<html><body><p><strong>【重大事項】</strong></p><p><a href=\"https://laohu8.com/S/00293\">國泰航空</a>(00293)購買十四架<a href=\"https://laohu8.com/S/BA\">波音</a>777-9型飛機</p><p><a href=\"https://laohu8.com/S/600276\">恆瑞醫藥</a>(01276)：注射用瑞康曲妥珠單抗聯合阿得貝利單抗注射液和化療用於胃癌或胃食管結合部腺癌適應症獲得美國 FDA孤兒藥資格認定</p><p><a href=\"https://laohu8.com/S/01177\">中國生物製藥</a>(01177) 自主研發的羅伐昔替尼片「TQ05105 (JAK/ROCK抑制劑)」被納入突破性治療藥物程序</p><p><a href=\"https://laohu8.com/S/02696\">復宏漢霖</a>(02696)：HLX79注射液聯合漢利康® 治療活動期腎小球腎炎的2期臨牀研究於中國境內完成首例患者給藥</p><p><a href=\"https://laohu8.com/S/01501\">瑛泰醫療</a>(01501)擬出資不超過1.1億元參設懷格廣泰基金</p><p><a href=\"https://laohu8.com/S/01783\">晉景新能</a>(01783)建議股份拆細</p><p><strong>【財報數據】</strong></p><p>國泰航空(00293)發佈中期業績 股東應占溢利36.51億港元 同比增長1.1% 中期息每股20港仙</p><p><a href=\"https://laohu8.com/S/00220\">統一企業中國</a>(00220)發佈中期業績，股東應占溢利12.87億元，同比增加33.24%</p><p><a href=\"https://laohu8.com/S/ONC\">百濟神州</a>(06160)發佈第二季度業績 淨利潤9432萬美元 同比扭虧為盈</p><p><a href=\"https://laohu8.com/S/00086\">新鴻基公司</a>(00086)發盈喜 預計中期股東應占溢利同比增加至不低於8億港元</p><p><a href=\"https://laohu8.com/S/02003\">維信金科</a>(02003)發盈喜，預期中期綜合淨利潤不少於2億元 同比大幅增長</p><p><a href=\"https://laohu8.com/S/09911\">赤子城科技</a>(09911)發盈喜 預計中期股東應占利潤同比增長約108.9%至126.7%</p><p><a href=\"https://laohu8.com/S/00334\">華顯光電</a>(00334)發盈喜 預期上半年母公司擁有人應占溢利同比增加不少於600%</p><p><a href=\"https://laohu8.com/S/00732\">信利國際</a>(00732)7月綜合營業淨額約14.68億港元，同比減少約3.3%</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股公告掘金 | 國泰航空上半年股東應佔溢利36.51億港元 百濟神州上半年業績扭虧為盈至9559萬美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股公告掘金 | 國泰航空上半年股東應佔溢利36.51億港元 百濟神州上半年業績扭虧為盈至9559萬美元\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2025-08-06 23:02</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p><strong>【重大事項】</strong></p><p><a href=\"https://laohu8.com/S/00293\">國泰航空</a>(00293)購買十四架<a href=\"https://laohu8.com/S/BA\">波音</a>777-9型飛機</p><p><a href=\"https://laohu8.com/S/600276\">恆瑞醫藥</a>(01276)：注射用瑞康曲妥珠單抗聯合阿得貝利單抗注射液和化療用於胃癌或胃食管結合部腺癌適應症獲得美國 FDA孤兒藥資格認定</p><p><a href=\"https://laohu8.com/S/01177\">中國生物製藥</a>(01177) 自主研發的羅伐昔替尼片「TQ05105 (JAK/ROCK抑制劑)」被納入突破性治療藥物程序</p><p><a href=\"https://laohu8.com/S/02696\">復宏漢霖</a>(02696)：HLX79注射液聯合漢利康® 治療活動期腎小球腎炎的2期臨牀研究於中國境內完成首例患者給藥</p><p><a href=\"https://laohu8.com/S/01501\">瑛泰醫療</a>(01501)擬出資不超過1.1億元參設懷格廣泰基金</p><p><a href=\"https://laohu8.com/S/01783\">晉景新能</a>(01783)建議股份拆細</p><p><strong>【財報數據】</strong></p><p>國泰航空(00293)發佈中期業績 股東應占溢利36.51億港元 同比增長1.1% 中期息每股20港仙</p><p><a href=\"https://laohu8.com/S/00220\">統一企業中國</a>(00220)發佈中期業績，股東應占溢利12.87億元，同比增加33.24%</p><p><a href=\"https://laohu8.com/S/ONC\">百濟神州</a>(06160)發佈第二季度業績 淨利潤9432萬美元 同比扭虧為盈</p><p><a href=\"https://laohu8.com/S/00086\">新鴻基公司</a>(00086)發盈喜 預計中期股東應占溢利同比增加至不低於8億港元</p><p><a href=\"https://laohu8.com/S/02003\">維信金科</a>(02003)發盈喜，預期中期綜合淨利潤不少於2億元 同比大幅增長</p><p><a href=\"https://laohu8.com/S/09911\">赤子城科技</a>(09911)發盈喜 預計中期股東應占利潤同比增長約108.9%至126.7%</p><p><a href=\"https://laohu8.com/S/00334\">華顯光電</a>(00334)發盈喜 預期上半年母公司擁有人應占溢利同比增加不少於600%</p><p><a href=\"https://laohu8.com/S/00732\">信利國際</a>(00732)7月綜合營業淨額約14.68億港元，同比減少約3.3%</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1326564.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSCEI","symbol_name":"國企指數","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1326564.html","article_id":"2557058673","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557058673","pubTimestamp":1754492564,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【重大事項】國泰航空(00293)購買十四架波音777-9型飛機恆瑞醫藥(01276)：注射用瑞康曲妥珠單抗聯合阿得貝利單抗注射液和化療用於胃癌或胃食管結合部腺癌適應症獲得美國 FDA孤兒藥資格認定中國生物製藥(01177) 自主研發的羅伐昔替尼片「TQ05105 (JAK/ROCK抑制劑)」被納入突破性治療藥物程序復宏漢霖(02696)：HLX79注射液聯合漢利康 治療活動期腎小球腎炎的2期臨牀","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688235":"百济神州","HSCEI":"国企指数","BK1095":"互动媒体与服务","06160":"百济神州","HSTECH":"恒生科技指数","ONC":"百济神州","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1115378108.SGD":"Eastspring Investments - Global Emerging Markets Dynamic AS SGD","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK1561":"航空股","BK4139":"生物科技","IE00BWDBJ730.SGD":"Legg Mason QS - MV Asia Pacific ex Japan Equity Growth and Income A Mdis SGD-H Plus","09911":"赤子城科技","BK0239":"医药制造","YANG":"三倍做空富时中国ETF-Direxion","BK1583":"高瓴概念","IE00BQJZWZ67.USD":"FRANKLIN MV ASIA PACIFIC EX JAPAN EQUITY GROWTH AND INCOME \"A\" (USD) INC (M) PLUS","BK1521":"挪威政府全球养老基金持仓","BK1123":"航空公司","00220":"统一企业中国","LU0640798160.USD":"EASTSPRING INVESTMENTS GLOBAL EMERGING MARKET DYNAMIC \"A\" (USD) ACC","BK4614":"Manus概念股","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1500":"做空集合股","BK1109":"应用软件","BK1237":"包装食品与肉类","IE00B0169L03.USD":"FSSA ASIA FOCUS FUND \"I\" (USD) ACC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","00086":"新鸿基公司","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","IE00B19Z5X02.USD":"Legg Mason QS - MV Asia Pacific ex Japan Equity Growth and Income A Acc USD","BK1549":"食品股","00293":"国泰航空","BK1188":"消费信贷","BK1588":"回港中概股","BK1161":"生物科技"},"translate_title":"Hong Kong Stock Announcement Nuggets | Cathay Pacific's profit attributable to shareholders in the first half of the year was HK $3.651 billion, BeiGene's first half performance turned losses into profits to US $95.59 million","themeId":"52663414aac120f847e3613d652edf81","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"00086":0.9,"00220":0.9,"00293":1,"06160":1,"09911":0.9,"HSCEI":1,"HSTECH":1,"ONC":1,"YANG":1},"content_text":"【重大事項】國泰航空(00293)購買十四架波音777-9型飛機恆瑞醫藥(01276)：注射用瑞康曲妥珠單抗聯合阿得貝利單抗注射液和化療用於胃癌或胃食管結合部腺癌適應症獲得美國 FDA孤兒藥資格認定中國生物製藥(01177) 自主研發的羅伐昔替尼片「TQ05105 (JAK/ROCK抑制劑)」被納入突破性治療藥物程序復宏漢霖(02696)：HLX79注射液聯合漢利康® 治療活動期腎小球腎炎的2期臨牀研究於中國境內完成首例患者給藥瑛泰醫療(01501)擬出資不超過1.1億元參設懷格廣泰基金晉景新能(01783)建議股份拆細【財報數據】國泰航空(00293)發佈中期業績 股東應占溢利36.51億港元 同比增長1.1% 中期息每股20港仙統一企業中國(00220)發佈中期業績，股東應占溢利12.87億元，同比增加33.24%百濟神州(06160)發佈第二季度業績 淨利潤9432萬美元 同比扭虧為盈新鴻基公司(00086)發盈喜 預計中期股東應占溢利同比增加至不低於8億港元維信金科(02003)發盈喜，預期中期綜合淨利潤不少於2億元 同比大幅增長赤子城科技(09911)發盈喜 預計中期股東應占利潤同比增長約108.9%至126.7%華顯光電(00334)發盈喜 預期上半年母公司擁有人應占溢利同比增加不少於600%信利國際(00732)7月綜合營業淨額約14.68億港元，同比減少約3.3%","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}